Immunoglobulin replacement and antimicrobial prophylaxis

A six-year-old boy with X-linked agammaglobulinaemia has been on intravenous immunoglobulin since infancy, dosed every four weeks in a hospital two hours from his home. He has had three breakthrough pneumonias this year despite a trough IgG that looks acceptable on paper. Two questions now decide his future. First, is the trough the wrong target — should his regimen be driven by his infection rate rather than the number? Second, would a switch to home subcutaneous immunoglobulin give him the steady troughs and the life back that his current regimen cannot? Holding those two questions together — dose to outcome, fit the route to the family — is the whole skill of this topic. [2] [7]

Overview & Definition

Immunoglobulin replacement is the regular administration of pooled human immunoglobulin G to restore the antibody that a child with a significant antibody deficiency cannot make for themselves. Antimicrobial prophylaxis is the scheduled use of an antibiotic, antiviral, or antifungal agent to prevent infection in a child whose immune system cannot reliably clear it. The two are used together, in sequence, or alone, depending on the defect, the infection burden, and the child's response. [1]

The unifying principle is that treatment is matched to a proven functional need, never to a number alone. Immunoglobulin replacement carries real costs and real risks — infusion reactions, headache, the rare but serious thrombotic, haemolytic, and renal events, line-related infection, and the dependence of a child on a blood product for life. Starting it without a confirmed defect trades a reversible or self-limiting problem for a permanent one. The same logic applies in reverse: a child with a real defect who is under-dosed to a textbook trough will keep infecting their lung. [2] [3]

The indications, dosing, and route choice rest on a defined evidence base. The American Academy of Allergy, Asthma and Immunology Primary Immunodeficiency Committee reviews, first in 2006 and updated in 2017, set out who benefits from immunoglobulin and on what evidence; the 2015 practice parameter frames the diagnostic and management standard; and the 2022 International Union of Immunological Societies classification names the conditions that qualify. A fellowship answer is built on these sources, not on a single regimen memorised from a formulary. [1] [4]

References10Show ledgerHide ledger

1. [1]Bonilla FA, Khan DA, Ballas ZK, et al. Practice parameter for the diagnosis and management of primary immunodeficiency. J Allergy Clin Immunol, 2015.PMID 26371839
2. [2]Perez EE, Orange JS, Bonilla F, Chinen J, Chinn IK, Dorsey M, et al. Update on the use of immunoglobulin in human disease: A review of evidence. J Allergy Clin Immunol, 2017.PMID 28041678
3. [3]Orange JS, Hossny EM, Weiler CR, Ballow M, Berger M, Bonilla FA, et al. Use of intravenous immunoglobulin in human disease: a review of evidence by members of the Primary Immunodeficiency Committee of the American Academy of Allergy, Asthma and Immunology. J Allergy Clin Immunol, 2006.PMID 16580469
4. [4]Bousfiha A, Moundir A, Tangye SG, et al. The 2022 Update of IUIS Phenotypical Classification for Human Inborn Errors of Immunity. J Clin Immunol, 2022.PMID 36198931
5. [5]Suez D, Stein M, Gupta S, et al. Efficacy, Safety, and Pharmacokinetics of a Novel Human Immune Globulin Subcutaneous, 20% in Patients with Primary Immunodeficiency Diseases in North America. J Clin Immunol, 2016.PMID 27582171
6. [6]Joud Hajjar, Nguyen AL, Constantine G, et al. Prophylactic Antibiotics Versus Immunoglobulin Replacement in Specific Antibody Deficiency. J Clin Immunol, 2020.PMID 31758281
7. [7]Pulvirenti F, Cinetto F, Pecoraro A, et al. Health-Related Quality of Life in Patients with CVID Under Different Schedules of Immunoglobulin Administration: Prospective Multicenter Study. J Clin Immunol, 2019.PMID 30644015
8. [8]Abolhassani H, Sadaghiani MS, Aghamohammadi A, Ochs HD, Rezaei N. Home-based subcutaneous immunoglobulin versus hospital-based intravenous immunoglobulin in treatment of primary antibody deficiencies: systematic review and meta analysis. J Clin Immunol, 2012.PMID 22730009
9. [9]Duff C, Ballow M Nuts and Bolts of Subcutaneous Therapy. Immunol Allergy Clin North Am, 2020.PMID 32654697
10. [10]Gathmann B, Grimbacher B, Beauté J, et al. The European internet-based patient and research database for primary immunodeficiencies: results 2006-2008. Clin Exp Immunol, 2009.PMID 19630863